Kailera’s lead candidate, ribupatide, is a once-weekly injectable GLP-1/GIP dual agonist being evaluated in three global Phase III trials.
The company’s pipeline also includes two oral GLP-1-based candidates and KAI-4729, a tri-agonist designed to target GLP-1, GIP and glucagon receptors.
The Kailera Therapeutics IPO brings a new public biotech into obesity drug development.
The Massachusetts-based company has four clinical-stage candidates spanning injectable, oral and multi-receptor GLP-1-based approaches. Kailera sold 44.9 million shares at $16 per share, generating $718.8 million in gross proceeds before underwriting discounts, commissions and other offering expenses.
Kailera’s common stock is listed on the Nasdaq Global Select Market under the ticker symbol KLRA.
Get industry leading pharma and biotech news, events and expert insights delivered to your inbox.
Kailera’s Obesity Pipeline
Kailera’s lead program is ribupatide, also known as KAI-9531. It is a once-weekly injectable GLP-1/GIP receptor dual agonist. GIP is another gut hormone involved in metabolic signaling.
Ribupatide is now being tested in KaiNETIC, Kailera’s global Phase III program. The program includes three trials in adults with obesity or adults who are overweight, with topline results expected in 2028.
The drug candidate already has late-stage data from China. In a 48-week Phase III trial conducted by Hengrui, people receiving the highest 6 mg dose had a mean 17.7% weight reduction, compared with 1.4% for placebo.
More than 2,500 clinical trial participants have been dosed with ribupatide across studies, including late-stage trials conducted by Hengrui in China.
KaiNETIC is split into three Phase III trials, each looking at a different patient group.
KaiNETIC-1 is enrolling adults with obesity or adults who are overweight and have at least one weight-related condition, excluding type 2 diabetes. KaiNETIC-2 is studying participants who are overweight and have type 2 diabetes. KaiNETIC-3 is focused on adults with a BMI of 35 or higher and no type 2 diabetes.
Kailera expects topline results from all three Phase III trials in 2028.
The company has also started a Phase IIb trial testing higher doses of ribupatide in adults with obesity and a BMI of 35 or higher. Results from that study are expected in 2027.
Kailera’s second program is oral ribupatide, a once-daily tablet version of the same peptide used in injectable ribupatide. The company plans to begin global Phase III trials of oral ribupatide as early as the first half of 2027, subject to discussions with the FDA and other regulators.
KAI-7535 is another oral candidate and a once-daily oral small molecule GLP-1 receptor agonist. Unlike peptide-based drugs, small molecules are typically easier to manufacture and formulate as pills.
Kailera initiated a Phase II trial of KAI-7535 in April 2026 and expects topline results in 2027.
Oral candidates are generally easier to take than injections. They are also easier to store in settings where refrigeration is harder to support.
Hengrui is also conducting a Phase III trial of the same candidate in China, with topline results anticipated in 2026.
KAI-4729 is Kailera’s once-weekly injectable tri-agonist, meaning it is designed to activate three hormone receptors: GLP-1, GIP and glucagon. Glucagon is a hormone involved in glucose and energy metabolism. Kailera plans to initiate a Phase I trial of KAI-4729 in 2026 and expects topline results in 2027.
Kailera’s pipeline was in-licensed through a collaboration with Hengrui. Kailera has raised $900 million since its inception.
Obesity Drug Development Beyond Kailera
As Kailera launches with an expansive obesity pipeline, other GLP-1 programs show progress and setbacks.
Pfizer saw a setback in April 2025 when it discontinued danuglipron, its oral GLP-1 receptor agonist, for chronic weight management, after a potential drug-induced liver injury case in a trial participant. Lilly, meanwhile, continues to study retatrutide, a GLP-1/GIP/glucagon tri-agonist, in several Phase III trials across obesity and related conditions.
Novo Nordisk’s CagriSema, a semaglutide and cagrilintide combination, missed the primary endpoint in a Phase III head-to-head trial against Zepbound. CagriSema showed 23% weight loss at 84 weeks versus 25.5% with Zepbound.
FAQs
What does it mean when a biotech company goes public through an IPO?
An IPO is when a company sells shares to public investors for the first time. For biotechs, that money often helps fund clinical trials, research and day-to-day operations.
What is a dual agonist in obesity drug development?
A dual agonist is a drug designed to activate two targets in the body. In obesity research, a GLP-1/GIP dual agonist targets two hormone pathways involved in appetite and metabolism.
What is a tri-agonist?
A tri-agonist is designed to activate three targets. Kailera’s KAI-4729 targets GLP-1, GIP and glucagon receptors, which are all involved in metabolism.
Why do obesity trials include people with type 2 diabetes?
Obesity and type 2 diabetes often occur together. Including people with and without diabetes helps researchers study how a drug works across different patient groups.
If you want your company to be featured on Xtalks.com, please email [email protected].
Join or login to leave a comment
JOIN LOGIN